Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis

Carcinogenesis

Volumn 29, Issue 4, 2008, Pages 846-848

  Baffa, Raffaele ^a   Fassan, Matteo ^a,d   Sevignani, Cinzia ^a   Vecchione, Andrea ^a,e   Ishii, Hideshi ^a,f   Giarnieri, Enrico ^a,g   Iozzo, Renato V ^b   Gomella, Leonard G ^a   Croce, Carlo M ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LZTS 1 PROTEIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INCIDENCE; CANCER MODEL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; TUMOR SUPPRESSOR GENE; UROTHELIUM;

ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; MALE; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 41849103802     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn006     Document Type: Article

References (23)

1. Jemal,A. et al. (2007) Cancer statistics,2007. CA Cancer J. Clin., 57, 43-66.
2. Baffa,R. et al. (2006) Molecular genetics of bladder cancer: targets for diagnosis and therapy. J. Exp. Clin. Cancer Res., 25, 145-160.
3. Ishii,H. et al. (1999) The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc. Natl Acad. Sci. USA, 96, 3928-3933.
4. Vecchione,A. et al. (2001) Fez1/lzts1 alterations in gastric carcinoma. Clin. Cancer Res., 7, 1546-1552.
5. Toyooka,S. et al (2002) Differential expression of FEZ1/LZS1 gene in lung cancers and their cell cultures. Clin. Cancer Res., 8 2292-2297.
6. Ono,K. et al. (2003) Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. Int. J. Oncol., 23, 297-302.
7. Nonaka,D. et al. (2005) Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. Cancer Res., 65, 1207-1212.
8. Ishii,H. et al. (2001) FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc. Natl Acad Sci. USA, 98 10374-10379.
9. Vecchione,A. et al. (2007) Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell, 11, 275-289.
10. Veechione,A. et al. (2002) FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am. J. Pathol., 160, 1345-1352.
11. Cabeza-Arvelaiz,Y. et al. (2001) Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene, 20, 4169-4179.
12. Knowles,M.A. et al. (2005) Mutation analysis of die 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett., 225, 121-130.
13. Lubet,R.A. et al. (2005) 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: Characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis, 26, 571-578.
14. Vecchione,A. et al. (2004) Inactivation of the FHIT gene favors bladder cancer development. Clin. Cancer Res., 10, 7607-7612.
15. Yaremko,M.L. et al. (1996) Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast, cancer. Genes Chromosomes Cancer, 16, 189-195.
16. Jenkins,R. et al. (1998) Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3NOMO prostate cancer Genes Chromosomes Cancer, 21, 131-143.
17. Wagner,U. et al. (1997) Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am. J. Pathol. 151, 753-759.
18. Knowles,M.A. (1999) The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int., 84, 412-427.
19. Choi,C. et al. (2000)Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder. Int. J. Cancer, 86, 501-505.
20. Grubbs,C.J. et al. (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fisher-344 rats: Cancer Res., 60 5599-5602.
21. Venkatachalam,S. et al. (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J., 17, 4657-4667.
22. Fero,M.L. et al. (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature, 396, 177-180.
23. Kwabi-Addo,B. et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl Acad. Sci. USA, 98, 11563-11568.